Clinical trials: Narcotic Abuse
Opioid Abuse (Disorder)
Nudges and Incentives to Enhance the Opioid Treatment Workforce
This project seeks to examine a critical barrier to optimizing the health care workforce for the treatment of opioid use disorders.
- Trial name
- NCT03834025
- Testing
- Phase 1 Condition 1, Phase 1 Condition 2, Phase 1 Condition 3
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Opioid Abuse
Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
The ability of pioglitazone (PIO) to alter the effects of opioids in humans has not been characterized in a controlled laboratory setting.
- Trial name
- NCT01395784
- Testing
- pioglitazone
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Healthy
A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted
The main purpose of this study is to determine if oxycodone and naltrexone combination capsules (ALO-02) have the potential to be abused when they are crushed and snorted.
- Trial name
- NCT01775189
- Testing
- crushed ALO-02 30 mg/3.6 mg, crushed oxycodone IR 30 mg
- Where
- Canada
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Pfizer
Opioid-Related Disorders
Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users
To determine the relative abuse potential of VYCAVERT (hydrocodone bitartrate and acetaminophen) compared to GENERIC H/A (hydrocodone bitartrate and acetaminophen) when crushed and administered intranasally to non dependent…
- Trial name
- NCT01759446
- Testing
- Generic H/A taken first, Vycavert taken first, Generic H/A plus i taken first
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Acura Pharmaceuticals Inc.
Opioid Abuse, Prescription Drug Abuse (Not Dependent)
Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool
The goal of the study is to validate a Prescription Drug Monitoring Program-based opioid risk metric to discriminate between low, moderate, and high-risk opioid use disorder.
- Trial name
- PHARMSCREEN (NCT03936985)
- Where
- 2 sites in United States
- Volunteers
- 1,464 people, healthy volunteers welcome
- Sponsor
- University of Utah
Cocaine Abuse, Opiate Dependence
Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8
The purpose of this study is to examine two medications, modafinil and citalopram, in the treatment of cocaine dependent individuals who are maintained on methadone.
- Trial name
- NCT00218036
- Testing
- Modafinil 200mg, Modafinil 400mg, Citalopram 20mg
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Substance Abuse, Intravenous, HIV
Change the Cycle: An RCT to Prevent Injection Initiation
The study will test the efficacy of a hour long, one-on-one, active listening counseling session (called Change the Cycle or CTC) aimed at reducing behaviors among active people who inject drugs (PWID) that research has found to…
- Conditions
- Substance Abuse, Intravenous, HIV, Heroin Dependence, Opioid Dependence
- Trial name
- CTC (NCT02774954)
- Testing
- Change the Cycle
- Where
- 2 sites in United States
- Volunteers
- 979 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Healthy
A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers
The main purpose of this study is to determine if oxycodone and naltrexone combination capsules (ALO-02) have the potential to be abused.
- Trial name
- NCT01746901
- Testing
- intact ALO-02 60 mg/7.2 mg, crushed ALO-02 60 mg/7.2 mg, crushed oxycodone IR 60 mg
- Where
- Canada
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Pfizer
Opioid Abuse
Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
The primary objective of this study is to compare the relative abuse potential of two different doses of orally administered Acurox Tablets to orally administered immediate-release (IR) oxycodone HCl tablets in non-dependent…
- Trial name
- NCT01030406
- Testing
- 40/0mg taken first, 80/0mg taken first, 40/240mg taken first
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Acura Pharmaceuticals Inc.
Opioid-Related Disorders, Substance-Related Disorders
Prescription Opioid Effects in Abusers Versus Non-Abusers
The purpose of this study is to examine the abuse liability of oxycodone in individuals with, and without, a history of prescription opioid abuse.
- Trial name
- NCT00158184
- Testing
- oxycodone 15 mg, oxycodone 30 mg
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Nalbuphine, Opioid Abuse
Oral Abuse Potential Study of Nalbuphine
The purpose of this study is to measure the effects of a drug called nalbuphine (an opioid drug) compared with the effects of hydromorphone (an opioid drug) and placebo (contains no active drug ingredients).
- Trial name
- NCT04018664
- Testing
- Nalbuphine HCl solution
- Where
- Canada
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Trevi Therapeutics
Narcotic Abuse
Aprepitant Effects on Oxycodone Response
Addressing the issue of opioid dependence and tolerance has public health implications for the treatment of opioid abuse (both heroin as well as pharmaceutical opioids) and for the treatment of pain.
- Trial name
- NCT00999544
- Testing
- Aprepitant 0mg, Aprepitant 40mg, Aprepitant 200mg
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Sharon Walsh
Opioid-related Disorders
Abuse Liability of Suboxone Versus Subutex
The study is designed to compare the abuse liabilities of intravenous buprenorphine and buprenorphine/naloxone in individuals who are physically dependent on sublingual buprenorphine.
- Trial name
- NCT00710385
- Testing
- Heroin, Naloxone, Low Bup Dose
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Heroin Dependence, Nicotine Dependence
Pioglitazone for Heroin and for Nicotine Dependence
The goal of the proposed research is to improve the effectiveness of treatments for opioid and for nicotine dependence by testing a novel pharmacological strategy.
- Trial name
- NCT01395797
- Testing
- PIO
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Opioid Sensitivity, Individual Difference
A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans
Within-subject, double-blind, placebo-controlled examination of opioid abuse potential in healthy individuals as a function of A118G SNP on the OPRM1 gene.
- Conditions
- Opioid Sensitivity, Individual Difference, Abuse Opioids
- Trial name
- NCT02360371
- Testing
- Within-subject test of blinded study medication
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Opioid Abuse
Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
The purpose of this study is to assess the abuse liability of 4 times (8 tablets) the usual recommended dose of Acurox (oxycodone HCl 40 mg plus niacin 240 mg) versus oxycodone HCL 40 mg alone in subjects with a history of opioid…
- Trial name
- NCT00699010
- Testing
- Acurox 5/30mg taken first, Oxycodone 5mg taken first
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Acura Pharmaceuticals Inc.